Αρχική World News Nivolumab Demonstrates Clinical Benefits in a Statistically Evaluable Number of Patients with...

Nivolumab Demonstrates Clinical Benefits in a Statistically Evaluable Number of Patients with CUP

An investigator-initiated phase II study is the first to show that nivolumab has clinical activity with manageable toxicity in a statistically evaluable number of patients with carcinoma of unknown primary (CUP). Treatment with nivolumab showed an objective response rate (ORR) of 22.2% in previously treated patients as determined by blinded independent central review (BICR), which met the primary endpoint. The results demonstrate a definite clinical benefit of nivolumab in patients with CUP; benefits were more apparent in patients with known biomarkers for immune checkpoint inhibitors (ICIs), such as PD-L1 expression, TMB and MSI status, while some patients responded well regardless of such biomarker status, implying the need for further biomarker evaluation in this disease population. The results are published on 26 November 2021 by Dr Hidetoshi Hayashi of the Department of Medical Oncology, Kindai University Faculty of Medicine in Osaka, Japan and colleagues in the Annals of Oncology

CUP is a heterogeneous clinical entity. Most patients with CUP are categorised into an unfavourable subset and receive empirical chemotherapy. Recent immune profiling of CUP with the use of immunohistochemistry and analysis of gene expression suggested that patients with CUP might receive clinical benefit from ICI treatment because their immune profiles are similar to those of patients with ICI-responsive malignancies. However, limited data are available regarding the clinical efficacy of ICIs for patients with CUP.

Given the recent approval of ICIs for several cancer types, the study team performed a multicentre phase II study to assess the efficacy of nivolumab for patients with CUP (UMIN000030649). Patients with CUP who were previously treated with at least one line of systemic chemotherapy constituted the principal study population. Previously untreated patients with CUP were also enrolled for exploratory analysis. Nivolumab 240 mg was administered every 2 weeks for up to 52 cycles. The primary endpoint was ORR in previously treated patients as determined by BICR according to RECIST v1.1.

In total, 56 patients with CUP were enrolled in the study. In 45 previously treated patients, the ORR was 22.2% (95% confidence interval [CI] 11.2–37.1%) with a median progression-free survival of 4.0 months (95% CI 1.9–5.8) and overall survival of 15.9 months (95% CI 8.4–21.5). Similar clinical benefits were also observed in 11 previously untreated patients.

Better clinical efficacy of nivolumab was apparent for tumours with a higher PD-L1 expression level, for those with a higher TMB, and for MSI–high tumours.

No differences in efficacy were found between tumour subgroups based on estimated tissue of origin.

Adverse events were consistent with the known safety profile of nivolumab. No treatment-related death was observed.

The authors concluded that their findings support the potential of nivolumab to become an additional therapeutic option for CUP, a disease with limited treatment options. They also wrote that a recent multicohort phase II study of pembrolizumab in advanced rare cancers included 22 patients with CUP. Among the 13 of these patients evaluable for objective response, the ORR according to immune-related RECIST was 23% (3 of 13 patients with a 95% CI of 5–54%). These results provide additional support for the use of ICIs in CUP treatment.

However, limitations of the current study include the lack of a comparator and the limited sample size. Another limitation is the difficulty associated with standardisation of CUP diagnosis. A lack of standardised applied definitions, classifications, and diagnostic work-up for CUP limits generalisation of the conclusions from a single study to the real world.

This study was funded by Ono Pharmaceutical Co. Ltd.

Reference

Tanizaki J, Yonemori K, Akiyoshi K, et al. Open-Label Phase II Study of the Efficacy of Nivolumab for Cancer of Unknown Primary. Annals of Oncology; Published online 26 November 2021. DOI: https://doi.org/10.1016/j.annonc.2021.11.009

Source

NEWSLETTER

Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like
57ΑκόλουθοιΑκολουθήστε

Διαβαστε Επίσης

Καρκίνος και Κορωνοϊός (COVID-19) ΜΕΡΟΣ Α

Εάν είστε καρκινοπαθής, το ανοσοποιητικό σας σύστημα μπορεί να μην είναι τόσο ισχυρό όσο κανονικά, έτσι μπορεί να ανησυχείτε για τους κινδύνους που σχετίζονται...

ΠΑΓΚΟΣΜΙΑ ΗΜΕΡΑ ΚΑΡΚΙΝΟΥ

Η Παγκόσμια Ημέρα Κατά του Καρκίνου καθιερώθηκε με πρωτοβουλία της Διεθνούς Ένωσης κατά του Καρκίνου (UICC), που εκπροσωπεί 800 οργανώσεις σε 155 χώρες του...

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ)

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...
- Advertisment -

Ροή Ειδήσεων

2-Year-Boy Is So Excited To See Himself In Disney’s ‘Encanto’

The importance of representation in media has been a growing topic of concern, and companies have responded by adding more diversity to their characters,...

Man Walks Entire Continent To Spread Awareness About Mental Health & Suicide Prevention

Matthew Fennell is walking over 3,000 miles across Australia for an important cause and one that is near and dear to his heart. Last year,...

Boy Battling Cancer Becomes Honorary Police Officer, Sworn In To 45 Agencies

At just ten years old, Devarjaye “DJ” Daniel has already been through more than most people go through in their entire lives. DJ has been...

Paclitaxel and Carboplatin Not Inferior When Compared with Paclitaxel and Ifosfamide for the Treatment of Patients with Uterine Carcinosarcoma

With regard to overall survival (OS), paclitaxel and carboplatin was not inferior and demonstrated improved progression-free survival (PFS) when compared with paclitaxel and ifosfamide...

Cancer in My Community: Improving Access to Palliative Care in Indonesia

Cancer in My Community is a Cancer.Net Blog series that shows the global impact of cancer and how people work to care for those with...

Should CAR T Cells Be Used Earlier in People with Non-Hodgkin Lymphoma?

January 13, 2022, by NCI Staff Several approved CAR T-cell therapies work by binding to the CD19 antigen on cancer cells and killing them. Credit: Adapted...